ATTAIN-MAINTAIN Phase 3

Can Oral Orforglipron Sustain Weight Loss?

Switching from Injectables to Daily Oral Monotherapy

Study design
Key protocol and randomization elements (52 weeks)
N=376 52 weeks RDBPC

Study schema

Screening and weight plateau verification
Adult patients after injectable therapy
Pre-rand.
(protocol)
1:1 randomization and blinding
Double-blind, placebo-controlled comparison
Day 0
Strat.
Maintenance phase
Daily oral monotherapy vs placebo
52
wk
Endpoint assessment
Body weight change and safety at week 52
W52
visit
Design rationale: assess whether the weight-loss effect is maintained when switching from injections to once-daily oral monotherapy under strict control (double-blind + placebo).

Protocol parameters

Population
Adults at a weight plateau after prior GLP‑1/dual-agonist therapy
Comparison (Arms)
Orforglipron (oral, once daily) vs placebo
Methodology
Randomized, double-blind, placebo-controlled study
Primary endpoint
Mean change in body weight (kg) at week 52 after switching
Safety
Adverse events and discontinuation due to AEs
Important for interpretation: results are presented by subgroups depending on prior injectable therapy (Wegovy vs Zepbound).

Prior Therapy: Wegovy

Switching from Semaglutide to Oral Orforglipron

+0.9 kg
Successful Maintenance

Result: Participants demonstrated superior maintenance with negligible mean weight change over one year. The oral pill effectively "locked in" the weight loss.

Prior Therapy: Zepbound

Switching from Tirzepatide to Oral Orforglipron

+5.0 kg
Moderate Regain

Result: Oral monotherapy could not fully sustain the peak efficacy of the dual-agonist injectable, resulting in a mean weight regain of 5kg.

Mean Weight Regain at 52 Weeks (kg)

Safety Profile

Discontinuation due to Adverse Events (AEs):

Orforglipron 4.8% - 7.2%
Placebo 6.3% - 7.6%
Consistent with GLP-1 class

Clinical Recommendation

Orforglipron is a viable, needle-free maintenance strategy for patients transitioning off injectables, particularly when the goal is to preserve prior weight loss with a daily oral option. Set expectations that “maintenance” may mean small drift rather than continued loss, and that adherence plus lifestyle support remain critical.

  • Best fit: patients at a verified weight plateau, motivated for daily dosing, and prioritizing injection-free long-term therapy.
  • Counseling focus: reinforce consistent dosing, nutrition/physical-activity plan, and realistic timelines (track trends over weeks, not days).
  • Safety/tolerability: review class-typical GI effects, hydration and meal-size strategies, and when to contact the clinic (persistent vomiting, dehydration, inability to maintain intake).
  • Follow-up: check weight trajectory and tolerability early after switch, then periodically; document goals (maintain vs further loss) and thresholds for escalation.

For prior Wegovy patients: emphasize that the oral regimen can generally maintain outcomes with minimal average change; frame success as stability and prevention of rebound.

For prior Zepbound patients: counsel that stepping down to oral monotherapy may lead to a modest rebound (~+5 kg on average) because dual-agonist peak efficacy may not be fully matched; agree in advance on a “regain threshold” that would prompt re-escalation (return to injectable, add/adjust adjuncts, or intensify lifestyle/behavioral support).

Decision checkpoints: if weight regain is clinically meaningful or comorbidity control worsens, consider resuming a more potent injectable strategy rather than persisting with ineffective maintenance.